Type Public (LSE: VEC) Revenue £72.0 million (2016) Net income £5.0 million (2016) | Industry Pharmaceuticals Operating income Founded 1997 | |
 | ||
Key people Bruno Angelici, Chairman
James Ward-Lilley, (CEO) Stock price VEC (LON) 153.38 GBX -0.72 (-0.46%)31 Mar, 5:01 PM GMT+1 - Disclaimer CEO James Ward-Lilley (Sep 2015–) Headquarters Chippenham, United Kingdom Subsidiaries Skyepharma, Vectura GmbH, Innovata Limited | ||
Vectura Group plc (LSE: VEC) is a British-based pharmaceuticals business. It is based in Chippenham and is a constituent of the FTSE 250 Index.
Contents
History
The company was formed in 1997 as a start-up pharmaceuticals business. In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies. In 2004 it was listed on the Alternative Investment Market. In 2007 it acquired Innovata plc, another developer of pulmonary products, and then moved on the full list of the London Stock Exchange. It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014. On 10 June 2016 Vectura completed a merger with Skyepharma; the merged company will continue to be known as Vectura.
Operations
The Group is a developer of inhaled therapies for the treatment of respiratory diseases.